Michael Pourdehnad, MD, Oncology, San Francisco, CA, UCSF Medical Center

MichaelPourdehnadMD

Oncology San Francisco, CA

Hematologic Oncology

Physician

Dr. Pourdehnad is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Pourdehnad's full profile

Already have an account?

Education & Training

  • UCSF
    UCSFFellowship, Hematology/Oncology, 2009 - 2012
  • Mount Sinai School of Medicine
    Mount Sinai School of MedicineResidency, Internal Medicine, 2005 - 2009
  • Chicago Medical School at Rosalind Franklin University
    Chicago Medical School at Rosalind Franklin UniversityClass of 2005

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2009 - 2022
  • NY State Medical License
    NY State Medical License 2007 - Present
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1
    Michael Pourdehnad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Career-Development Lunch Sessions: Industry Careers 
    60th American Society of Hematology Annual Meeting - 12/1/2018

Press Mentions

  • Deadliest Cancers May Respond to New Drug Treatment Strategy
    Deadliest Cancers May Respond to New Drug Treatment StrategyJanuary 29th, 2016
  • Deadliest Cancers May Respond to New Drug Treatment Strategy
    Deadliest Cancers May Respond to New Drug Treatment StrategyJanuary 29th, 2016

Hospital Affiliations